Bio Roundup: Pelosi’s Reveal, Alder’s Deal, Biogen’s Fails & More

(Page 2 of 2)

human testing for Duchenne and Becker muscular dystrophies.

—IGM Biosciences (NASDAQ: IGMS) tallied $175 million in an IPO to back antibody drugs for cancer.

—Exagen (NASDAQ: XGN), which sells diagnostic blood tests for autoimmune diseases, raised $50 million in an IPO.

—Pain drug developer Centrexion Therapeutics revived its IPO plans after pulling its potential offering last November.

—Chinese biosimilar developer Shanghai Henlius Biotech nabbed $410 million in a Hong Kong IPO.

Bayer led a $40 million Series B investment in OneDrop, a New York startup whose software uses artificial intelligence to encourage behavioral changes intended to manage diabetes.


Gary Gilliland, director and president of the Fred Hutchinson Cancer Research Center, will step down next year … Neil McFarlane left Retrophin (NASDAQ: RTRX) to become CEO of Adamas Pharmaceuticals (NASDAQ: ADMS) … Infinity Pharma’s Samuel Agresta jumped to Foghorn Therapeutics to become chief medical officer … Ethan Perlstein was appointed chief scientific officer of the Christopher & Dana Reeve Foundation … former Orchard Therapeutics (NASDAQ: ORTX) executive Jason Meyenburg surfaced as CEO of Gemini Therapeutics … Pol Boudes is stepping down as chief medical officer of Cymabay Therapeutics (NASDAQ: CBAY) … Allen Poirson left VC firm Mighty Capital to become senior vice president of biopharmaceutical development at twoXAR … and Black Diamond Therapeutics tapped Christopher Roberts of SR One to become its chief scientific officer.

Ben Fidler and Frank Vinluan contributed to this report.

Photo of US Capitol by Kevin Dooley via Creative Commons.

Single PageCurrently on Page: 1 2 previous page